Home・Aktien・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Geschlossen

4.11 -0.24

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.01

Max

4.23

Schlüsselkennzahlen
By Trading Economics
Einkommen	-136K -35M
EPS	-0.503
Angestellte	106
EBITDA	2.2M -35M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+86.75% upside

Dividenden
By Acuity
Nächstes Ergebnis	6. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	36M 331M
Vorheriger Eröffnungskurs	4.35
Vorheriger Schlusskurs	4.11

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Aug. 2026, 23:56 UTC

Coherent Corp shares are higher in after-market trading, continuing a strong upward trend since Tuesday's close amid broader market volatility and fluctuating oil prices.

11. Aug. 2026, 23:56 UTC

Paychex Inc. shares are higher in after-market trading, maintaining a position above its 20-day moving average amid recent volatility in Brent crude oil prices.

11. Aug. 2026, 23:56 UTC

Arcos Dorados Holdings shares are higher in after-market trading, despite five consecutive lower sessions. Market volatility is influenced by rising Brent crude oil prices.

11. Aug. 2026, 23:56 UTC

Citizens Financial Group Inc shares are higher in after-hours trading, remaining above their 20-day moving average and near the upper end of their one-month range.

11. Aug. 2026, 23:56 UTC

News

GrowGeneration reports second-quarter net sales of $43.2 million, a 5.5% increase. Shares are higher in after-market trading following the earnings announcement.

11. Aug. 2026, 23:56 UTC

Assurant Inc. shares rose after-market, recovering from an early dip amid broader market volatility linked to Brent crude oil fluctuations and investor caution ahead of CPI data.

11. Aug. 2026, 23:56 UTC

News

Digital Realty Trust announced a quarterly dividend of $1.22 per share. Shares are trading higher in after-market hours following the announcement.

11. Aug. 2026, 23:56 UTC

Macy's Inc. shares are higher in after-market hours, driven by notable strength in the Broadline Retail sub-sector, despite no specific company news identified.

11. Aug. 2026, 23:56 UTC

Monro Inc shares are trading higher in after-market hours amid broader market volatility and rising Brent crude oil prices above $90 per barrel.

11. Aug. 2026, 23:56 UTC

Social Media

Twilio Inc shares are higher in after-market hours, supported by social media discussions on a "massive stage 1 base breakout" and increased full-year guidance.

11. Aug. 2026, 23:56 UTC

Kaiser Aluminum Corp shares are higher in after-market trading. The stock remains above its 20-day moving average amid broader market volatility.

11. Aug. 2026, 23:56 UTC

Alibaba Group Holding Ltd shares are higher in after-market trading, reflecting routine performance within a narrow range above the 20-day moving average.

11. Aug. 2026, 23:56 UTC

CH Robinson Worldwide shares are trading higher in after-market hours, reflecting some resilience amid broader market volatility and fluctuating Brent crude oil prices.

11. Aug. 2026, 23:56 UTC

Fluence Energy Inc shares are higher in after-market hours, trading within a narrow range. No specific news was identified to explain the movement.

11. Aug. 2026, 23:56 UTC

Chemours Co shares are higher in after-market trading, reflecting notable activity since Tuesday's close. The stock remains below its 20-day moving average.

11. Aug. 2026, 23:56 UTC

Genco Shipping & Trading Ltd shares are higher in after-market trading, rising from session lows despite being below its 20-day moving average and near a one-month low.

11. Aug. 2026, 23:56 UTC

Broadridge Financial Solutions Inc shares are higher in after-market trading, recovering from a session dip and remaining above the 20-day moving average.

11. Aug. 2026, 23:56 UTC

News

UBS maintains Buy rating on Rapid7 and raises price target to $12. Shares are trading higher in after-market hours, reflecting positive investor sentiment.

11. Aug. 2026, 23:56 UTC

Kraft Heinz Co shares are trading slightly higher in after-market hours. No specific news was identified to explain this movement.

11. Aug. 2026, 23:56 UTC

PennyMac Mortgage Investment Trust shares are higher in after-market trading, reflecting a slight uptick amid broader market volatility. No specific news was identified.

11. Aug. 2026, 23:56 UTC

Correlated Moves

American Water Works Company reported no specific news after-market hours. The stock was roughly flat, reflecting broader market sentiment and stability.

11. Aug. 2026, 23:56 UTC

Atmos Energy Corp shares are trading higher in after-market hours. This movement occurs amid broader market volatility and fluctuating Brent crude oil prices.

11. Aug. 2026, 23:56 UTC

Axon Enterprise Inc. shares are lower in after-market trading, despite a recent trend of three consecutive higher daily closes.

11. Aug. 2026, 23:52 UTC

ETF Constituents

Correlated Moves

Macro News

iShares MSCI South Korea ETF rises in after-market trading, supported by technology stock gains and broader equity market movements. It remains above its 20-day moving average.

11. Aug. 2026, 23:52 UTC

Monster Beverage Corp. shares rose during after-market hours, recovering from a slight pullback. Market focus remains on upcoming economic data, including the CPI report.

11. Aug. 2026, 23:52 UTC

Social Media

Entravision Communications Corp shares are rising in after-market trading amid positive investor sentiment and discussions of potential favorable price movements.

11. Aug. 2026, 23:52 UTC

Correlated Moves

Booking Holdings Inc shares are lower in after-market hours amid broader market declines. Investors await the upcoming consumer price index report for further guidance.

11. Aug. 2026, 23:51 UTC

Xpeng Inc. shares were roughly flat in after-market trading. Market attention remains on the upcoming consumer price index report amid recent job loss data.

11. Aug. 2026, 23:51 UTC

Correlated Moves

Cohu Inc. shares are lower in after-market trading, influenced by a slight decline in the Nasdaq 100 Index and overall market sentiment.

11. Aug. 2026, 23:51 UTC

Eton Pharmaceuticals Inc shares are lower in after-market trading amid unusual volatility. No specific news was identified to explain the decline.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

86.75% Vorteil

12-Monats-Prognose

Durchschnitt 7.75 USD 86.75%

Hoch 11 USD

Tief 4 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Zentalis Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.